Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, particularly in patients with BRCA1/2 mutations, according to results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center.

👉 Full Story